AMGEN INC Company Profile

✉ Email this page to a colleague

AMGEN INC has four approved drugs.

There are fifteen US patents protecting AMGEN INC drugs.

There are two hundred and seventy-five patent family members on AMGEN INC drugs in fifty-one countries and sixteen supplementary protection certificates in fifteen countries.

International Patents:	275
US Patents:	15
Tradenames:	3
Ingredients:	4
NDAs:	4
Drug Master File Entries:	9
Patent Litigation for AMGEN INC:	See patent lawsuits for AMGEN INC
PTAB Cases with AMGEN INC as petitioner:	See PTAB cases with AMGEN INC as petitioner
PTAB Cases with AMGEN INC as patent owner:	See PTAB cases with AMGEN INC as patent owner

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No	11,236,091	⤷ Subscribe	Y	Y		⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Amgen Inc	CORLANOR	ivabradine	SOLUTION;ORAL	209964-001	Apr 22, 2019		RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-001	Apr 15, 2015	AB	RX	Yes	No	7,867,996*PED	⤷ Subscribe			Y	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	7,893,101	⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	8,455,536	⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	8,802,717	⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	8,802,717	⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	7,659,302	⤷ Subscribe
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	6,020,358	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	2019C/008	Belgium	⤷ Subscribe	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION
2962690	2019/037	Ireland	⤷ Subscribe	PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/981 20150115
2962690	132019000000096	Italy	⤷ Subscribe	PRODUCT NAME: APREMILAST(OTEZLA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/981, 20150116
2962690	C02962690/01	Switzerland	⤷ Subscribe	VERTRETERLOESCHUNG
2962690	37/2019	Austria	⤷ Subscribe	PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 (MITTEILUNG) 20150116
2962690	C20190029 00295	Estonia	⤷ Subscribe	PRODUCT NAME: APREMILAST;REG NO/DATE: EU/1/14/981 16.01.2015
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.